← All trials
NCT05057013
Phase 1/Phase 2Interventional
Trials that are a combination of phases 1 and 2.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 31, 2021
- Primary completion
- Sep 30, 2026
- Completion date
- Sep 30, 2026
- First posted
- Sep 27, 2021
- Last posted
- Oct 19, 2021
- Enrollment
- 135
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Cancer Research UKLead sponsor
- Royal Marsden Hospital NHS TrustOverall official - principal investigator
- Cancer Research UKStudy director
- Hummingbird Bioscience, Inc.Collaborator
Drugs studied
Indications studied
- Squamous Cell Carcinoma of Head and Neck
- Urinary Bladder Neoplasms
- Carcinoma, Non-Small-Cell Lung
- Uterine Cervical Neoplasms
- Esophageal Neoplasms
- Carcinoma, Hepatocellular
- Melanoma
- Ovarian Neoplasms
- Pancreatic Neoplasms
- Stomach Neoplasms
- Colorectal Neoplasms
- Endometrial Neoplasms
- Prostatic Neoplasms, Castration-Resistant
- Triple Negative Breast Neoplasms
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.